Project 4: Nuclease Inhibitors for Viruses of Pandemic Concern
项目 4:针对流行病病毒的核酸酶抑制剂
基本信息
- 批准号:10522813
- 负责人:
- 金额:$ 304.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoV5&apos-exoribonucleaseAddressAnimal ModelAntiviral AgentsAntiviral ResponseArenavirusBindingBiochemicalBiological AssayBolivian Hemorrhagic Fever VirusCOVID-19 screeningCell Culture TechniquesCell modelCellsChemicalsChemistryCollaborationsComplementComplexComputer ModelsCryoelectron MicroscopyDNADoseEffectivenessEnsureEnzymesExoribonucleasesFDA approvedFluorescenceGenerationsGenomeGoalsIn VitroInfectionInterferonsIonsJunin virusKineticsKnockout MiceLassa virusMetalsMidwestern United StatesMolecularMutagenesisNonstructural ProteinNucleoproteinsPathogenicityPharmaceutical ChemistryPharmaceutical PreparationsPharmacodynamicsPlayPropertyRNARNA chemical synthesisRNA replicationRNA-Directed RNA PolymeraseRepliconResistanceResolutionRibavirinRoleSARS-CoV-2 infectionSTAT1 geneStructureStructure-Activity RelationshipTechnologyTestingTransgenic MiceVaccinesValidationViralViral Hemorrhagic FeversViral PathogenesisVirusVirus DiseasesVirus InhibitorsVirus ReplicationWorkX-Ray Crystallographyanimal facilityaptamerbasedesigndrug candidateeffective therapyefficacy evaluationefficacy testinggain of functionhigh throughput screeningimprovedinhibitorlaboratory facilitymolecular dynamicsmouse modelnew therapeutic targetnovelnucleasenucleoside analogpandemic diseasepharmacokinetics and pharmacodynamicspreferenceremdesivirresistance mutationresponsestructural biologysynergismviral RNAvirtual screening
项目摘要
Project 4 – Nuclease Inhibitors for Viruses of Pandemic Concern
Abstract
SARS-CoV-2 (SARS2) and highly pathogenic arenaviruses including Lassa virus (LASV), Junin virus, and
Machupo virus share a structurally and functionally related 3'-to-5' exoribonuclease (ExoN) domain, which plays
essential roles in proofreading during RNA syntheses by the error-prone viral RNA-dependent RNA polymerase
(RdRp) and suppressing host antiviral responses. Project 4 is pursuing chemical inhibition of ExoN from these
viruses of pandemic concern, with the goal of blocking viral replication by lethal mutagenesis as well as mitigating
viral pathogenesis by reactivating host’s interferon responses. Our team has contributed extensively to the
structural and functional understanding of these viral ExoN enzymes, including the elucidation of their first atomic
structures and characterization of catalytic mechanisms. We have also developed robust fluorescence-based
assays to quantitatively analyze the ExoN catalytic activities, including a novel assay featuring fluorogenic RNA
aptamer substrates that enables a gain-of-function readout in ultra-high-throughput screening (uHTS).
Furthermore, we have used DNA-encoded chemistry technology (DEC-Tec) to obtain selective binders to
SARS2 ExoN and LASV nucleoprotein (NP) containing the ExoN domain. Building on these prior and preliminary
studies, we will continue to work closely with Core B and use 3 complementary approaches (uHTS, DEC-Tec,
and Virtual screening) to identify first-in-class viral ExoN inhibitors. We will then leverage the deep expertise of
Core C and Core D in medicinal chemistry and structural biology, respectively, to enhance the potency,
selectivity, and pharmacodynamic/kinetic properties of hit compounds for detailed antiviral studies in cell and
animal models by Core E. These studies will deliver antiviral drug candidates with a distinct mechanism of action
to complement those developed against established antiviral targets including RdRp, helping to address the
critical need for novel antiviral drugs against both SARS2 and the highly pathogenic arenaviruses that cause
fatal hemorrhagic fever infections.
项目4 -大流行病毒的核酸酶抑制剂
摘要
SARS-CoV-2(SARS 2)和高致病性沙粒病毒,包括拉沙病毒(LASV)、朱宁病毒和
马丘波病毒共享一个结构和功能相关的3 '至5'核糖核酸外切酶(ExoN)结构域,
在由易错病毒RNA依赖性RNA聚合酶进行RNA合成过程中校对的重要作用
(RdRp)和抑制宿主抗病毒应答。项目4正在寻求对这些ExoN的化学抑制
大流行关注的病毒,目的是通过致命诱变阻断病毒复制,
通过重新激活宿主的干扰素反应来引起病毒发病。我们的团队为
这些病毒ExoN酶的结构和功能的理解,包括阐明其第一个原子
催化机理的结构和表征。我们还开发了基于荧光的
定量分析ExoN催化活性的测定,包括一种以荧光RNA为特征的新型测定
适体底物,其能够在超高通量筛选(uHTS)中进行功能获得性读出。
此外,我们使用DNA编码化学技术(DEC-Tec)来获得选择性结合剂,
SARS 2 ExoN和含有ExoN结构域的LASV核蛋白(NP)。基于这些先前和初步的
研究,我们将继续与核心B密切合作,并使用3种互补方法(uHTS,DEC-Tec,
和虚拟筛选)以鉴定一流的病毒ExoN抑制剂。然后我们将利用
核心C和核心D分别在药物化学和结构生物学,以提高效力,
选择性和药效学/动力学特性,用于细胞中的详细抗病毒研究,
动物模型的核心E。这些研究将提供具有独特作用机制的抗病毒候选药物
以补充针对包括RdRp在内的已确定的抗病毒靶点开发的药物,
迫切需要针对SARS 2和高致病性沙粒病毒的新型抗病毒药物,
致命的出血热感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hideki Aihara其他文献
Hideki Aihara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hideki Aihara', 18)}}的其他基金
Structural studies of viral replication and invasion
病毒复制和侵袭的结构研究
- 批准号:
10337889 - 财政年份:2016
- 资助金额:
$ 304.02万 - 项目类别:
Structural studies of viral replication and invasion
病毒复制和侵袭的结构研究
- 批准号:
10544179 - 财政年份:2016
- 资助金额:
$ 304.02万 - 项目类别:
Crystallographic studies of retroviral intasome complexes
逆转录病毒嵌体复合物的晶体学研究
- 批准号:
8919420 - 财政年份:2014
- 资助金额:
$ 304.02万 - 项目类别:
相似国自然基金
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
- 批准号:81300507
- 批准年份:2013
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
P1082 - Revealing Mercer 5's Pulsar Population with Parkes
P1082 - 揭秘默瑟 5
- 批准号:
Local : csiro:P1082 - 财政年份:
- 资助金额:
$ 304.02万 - 项目类别: